Workshop Presentation to Highlight the Potential of AI-Driven Molecular Profiling in Tumors
Poster Presentation Unveils Advancements in Genomic Reference Standards for Validating WES Assays
WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 – 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT. During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.
Details of BostonGene’s presence at AMP are below:
Title: Unraveling Tumor Profiles Using an HRD-Enabled CGP Assay and Exome Sequencing with AI-Driven Data Analysis
Date and Time: Wednesday, November 15 | 2:00 PM
Location: 255EF, Second Level
Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene
Tumor molecular characterization is key for advancing precision oncology. In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses. The approach combines whole exome sequencing based on Agilent SureSelect technology with BostonGene’s AI-driven best-in-class analytics to identify SNVs, indels, CNAs, TMB, MSI, HRD, and translocations.
Title: Developing Bespoke Genomic Reference Standards for Validating Somatic Mutation Detection in Clinical Whole Exome Sequencing Assays
Date and Time: Friday, November 17 | 9:15 AM – 10:15 AM
Location: Salt Palace Convention Center
Presenter: Anastasiya Yudina, BostonGene
With the increasing use of whole exome sequencing (WES) in precision oncology on FFPE tumor samples, the establishment of robust validation procedures to ensure accurate and reliable WES assay results is necessary. While germline variant calling reference standards are common, reference standards for somatic variant calling require optimization to be used for WES assay validation at the exome-wide level. To address these challenges, BostonGene developed a method for obtaining reference standards and established optimal thresholds for accurate somatic mutation calling in FFPE samples.
About BostonGene Corporation
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.